Clinical trials: SBRT
Advanced Malignant Pleural Mesothelioma
Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma
This is a multi-centre non-randomised open-label phase 1 trial of pembrolizumab given in combination with SBRT to part of a pleural-based lesion in patients with unresectable MPM.
- Trial name
- MESO-PRIME (NCT04166734)
- Testing
- Pembrolizumab, Stereotactic Body Radiotherapy (SBRT)
- Where
- 2 sites in United Kingdom
- Volunteers
- 5 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Pancreatic Cancer, Pancreatic Adenocarcinoma
Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
The objective of this study is to estimate the R0 resection rate in patients with Resectable Pancreatic Ductal Adenocarcinoma (R-PDAC) as well as those with Resectable Pancreatic Ductal Adenocarcinoma (BR-PDAC) independently in…
- Conditions
- Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreas Ductal Adenocarcinoma
- Trial name
- NCT02723331
- Testing
- Nab paclitaxel, Gemcitabine
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Academic Thoracic Oncology Medical Investigators Consortium
Metastatic Non-small Cell Lung Cancer, Metastatic Triple-negative Breast Cancer
SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC
This is a Phase II trial to determine the efficacy and safety of stereotactic body radiation therapy (SBRT) and in situ oncolytic virus therapy used as a window of opportunity treatment before pembrolizumab in patients with…
- Trial name
- STOMP (NCT03004183)
- Testing
- ADV/HSV-tk, Valacyclovir, SBRT
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- The Methodist Hospital Research Institute
Carcinoma, Non-Small-Cell Lung
Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer
The purpose of this study is to find out the effectiveness of the drug durvalumab (MEDI4736) with or without stereotactic body radiation therapy (SBRT) as treatment for stage I (tumors > 2cm), II, and IIIA non-small cell lung…
- Trial name
- NCT02904954
- Testing
- Durvalumab, Durvalumab plus SBRT
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Weill Medical College of Cornell University
Primary Tumor, Metastatic Cancer
Randomized Study of Stereotactic Body Radiotherapy vs. Conventional Radiation for Spine Metastasis
The purpose of this study is to determine how effective SBRT is compared to traditional radiation in treating the cancer that has spread to your spine and is causing pain.
- Trial name
- NCT01525745
- Testing
- Radiosurgery/SBRT, External Beam Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Beth Israel Deaconess Medical Center
Metastatic Melanoma
Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.
The purpose of this study is compare the response rates in patients with metastatic melanoma treated with high-dose IL-2 to patients treated with high-dose IL-2 along with radiation therapy.
- Trial name
- SBRT/IL-2 (NCT01416831)
- Testing
- Radiation therapy and high-dose IL-2, High-dose IL-2
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Providence Health & Services
Lung Cancer
Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00843726
- Testing
- Arm 1 stereotactic body radiation therapy, Arm II stereotactic body radiation therapy
- Where
- 3 sites in United States
- Volunteers
- 98 people
- Sponsor
- Roswell Park Cancer Institute
Hepatocellular Carcinoma, Liver Cancer
Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma
This study is to determine the safety and efficacy of stereotactic body radiotherapy (SBRT) and treatment drug in patients with hepatocellular carcinoma.
- Trial name
- RAD 0901 (NCT01005875)
- Testing
- Sorafenib, Stereotactic Body Radiotherapy (SBRT)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Alabama at Birmingham
Liver Cancer
Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Metastatic Tumors to the Liver
The purpose of this study is to determine the response of liver tumors to radiation therapy using Tomotherapy.
- Trial name
- NCT01030757
- Testing
- Tomotherapy treatment
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- New Mexico Cancer Research Alliance
Lung Cancer
Pilot Study of SGRT Alone vs. SGRT With Fiducials for Breath Hold SBRT tx of the Lung
This is a pilot study designed to to provide data and experience comparing two different techniques of breath hold SBRT treatments. The first technique will include SGRT, but with the assistance of implanted fiducials.
- Trial name
- NCT04060927
- Testing
- SGRT
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Wake Forest University Health Sciences
Lung Cancer
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00750269
- Testing
- SBRT 40.0 Gy, SBRT 42.5 Gy, SBRT 45.0 Gy
- Where
- 58 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Radiation Therapy Oncology Group
Sarcoma, Thoracic Cancer
Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers
This is a study evaluating the safety and efficacy of Lattice SBRT for patients with large tumors (≥ 4.5 cm) planning to undergo palliative radiotherapy.
- Conditions
- Sarcoma, Thoracic Cancer, Abdominal Cancer, Pelvic Cancer
- Trial name
- NCT04553471
- Testing
- Stereotactic body radiotherapy, Research blood draw
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Washington University School of Medicine
Vertebral Metastasis
Phase II Trial of Stereotactic Radiation Therapy (SRT) Versus SRT Plus Vertebral Augmentation Procedure (VAP) for Vertebral Metastasis
The purpose of this study is to determine pain control rate (Percentage of patients in each arm that achieve pain control) at the treated site(s) at 1 month, 2-4 months and 5-6 months post-treatment.
- Trial name
- NCT01527292
- Testing
- Stereotactic Radiation Therapy, SRT with Vertebral Augmentation Procedure
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Louisville
Pancreatic Neoplasms, Pancreatic Cancer
Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer
Background: Stereotactic body radiation therapy (SBRT) is used to treat cancer. It is a way of giving very focused beams of radiation to tumors.
- Conditions
- Pancreatic Neoplasms, Pancreatic Cancer, Cancer of Pancreas, Cancer of the Pancreas
- Trial name
- NCT02311361
- Testing
- Durvalumab, Tremelimumab, Sterostatic body radiation therapy (SBRT)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Head and Neck Squamous Cell Carcinoma, Second Primary Squamous Cell Carcinoma of the Head and Neck
Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer
This phase I/II trial studies the side effects and how well bintrafusp alfa and stereotactic body radiation therapy work in treating patients with head and neck squamous cell cancer that has come back (recurrent) or has occurred…
- Trial name
- NCT04220775
- Testing
- Bintrafusp Alfa, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Prostatic Neoplasms
Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
This is a non-comparative open-label multicenter Phase 2 clinical trial combining stereotactic body radiation therapy (SBRT) and pembrolizumab with or without intratumoral SD-101 in participants with newly diagnosed hormone-naive…
- Trial name
- NCT03007732
- Testing
- Pembrolizumab, SD-101, Leuprolide acetate
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- David Oh
Prostate Cancer
Hypofractionated SBRT For Prostate Cancer
The purpose of this study is to determine, in both low-risk and intermediate-risk cohorts, the rates of acute and late grade 3 or higher gastrointestinal and genitourinary toxicity observed during a 24 month follow up and to…
- Trial name
- NCT00977860
- Testing
- Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 163 people
- Sponsor
- Adam Olson
Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.
The purpose of this study is to evaluate if the combination of nivolumab and a CCR2/CCR5 dual antagonist (BMS-813160) with GVAX is safe in patients with locally advanced pancreatic cancer (LAPC) who have received chemotherapy and…
- Trial name
- NCT03767582
- Testing
- Stereotactic Body Radiation (SBRT), Nivolumab, CCR2/CCR5 dual antagonist
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Spinal Neoplasms
Evaluation of Single Session Stereotactic Body Radiotherapy
The goal of this clinical research study is to find out if stereotactic body radiotherapy to the spine using computerized tomography (CT)-on-Rails is safe and effective in the treatment of metastatic spine tumors.
- Trial name
- NCT00492817
- Testing
- Stereotactic Body Radiotherapy
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
MRI Guided SBRT for Localized Prostate Cancer
This study utilizes advanced imaging techniques (mpMRI prostate scan) to select and stratify patients for two different radiotherapy regimens based on the presence/absence of identifiable intraprostatic lesions.
- Trial name
- NCT03778112
- Testing
- SBRT to whole prostate, IMRT followed by mpMRI guided SBRT boost with SIB to intraprostatic lesions
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Rush University Medical Center